Search
Neurocrine Biosciences Inc
NBIXAdd to Watchlist
146.230USD
-5.600-3.69%
Close 09-18 16:00（ET）
14.85BMarket Cap
21.82P/E TTM
Neurocrine Biosciences Inc (NBIX) Stock Price Target & Forecast
Analyst Rating
Based on 30 analysts giving stock ratings to Neurocrine Biosciences Inc in the past month.
Buy
12 Strong Buy
14 Buy
4 Hold
0 Sell
0 Strong Sell
Target Price
209.195USD+37.78%
NBIX Analyst Recommendation Trends
In the current month, NBIX has received 14 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the last month is 209.195.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
12
12
12
12
11
11
11
10
14
14
15
14
14
15
15
15
4
4
4
4
4
4
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30
30
31
30
29
30
30
29
NBIX Analyst Rating for Peer Comparison
Updated: Sep 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
7
17
12
1
0
37
Amgen Inc
AMGN
4
12
18
2
1
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Pfizer Inc
PFE
5
6
19
1
1
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Financial Forecasting
Based on analysts' estimates, NBIX EPS is projected to reach 1.904 in FY2026Q3, following reported EPS of 1.430 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
1.88
1.17
1.34
1.90
1.85
Actual
1.54
1.97
1.43
--
--
Surprise
-18.40%
+67.68%
+6.51%
--
--
FAQs
What is Neurocrine Biosciences Inc's expected revenue for the next quarter?
Neurocrine Biosciences Inc's expected revenue is 1.04B.
What is Neurocrine Biosciences Inc's price target?
Analysts forecast that Neurocrine Biosciences Inc's price target is USD 209.20, with the highest forecast at USD 253.00 and the lowest forecast at USD 165.00.
How have Neurocrine Biosciences IncNBIX's recent earnings per share performed?
The market expectation was USD 1.43, while Neurocrine Biosciences IncNBIX's earnings per share (EPS) for the previous quarter was USD 1.97. EPS for the next quarter is expected at USD 1.90.
What is the analyst rating for Neurocrine Biosciences Inc?
Based on the ratings of Neurocrine Biosciences Inc's stock from 30 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.